Spectrum Pharmaceuticals Inc. [NASDAQ: SPPI] price surged by 2.78 percent to reach at $0.03. The company report on September 10, 2022 that Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC). The data show that poziotinib is highly active in G778 mutations in both treatment naïve and previously treated patients with NSCLC.
The poster titled “High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC)” is being presented by Xiuning Le, M.D., Ph.D., Assistant Professor, The University of Texas MD Anderson Cancer Center on September 12, 2022. A poster with the data is available to registered participants at the European Society for Medical Oncology Congress (ESMO) 2022 taking place in Paris from September 9-13, 2022.
A sum of 9581472 shares traded at recent session while its average daily volume was at 2.70M shares. Spectrum Pharmaceuticals Inc. shares reached a high of $1.30 and dropped to a low of $1.21 until finishing in the latest session at $1.29.
The one-year SPPI stock forecast points to a potential upside of 76.96. The average equity rating for SPPI stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Spectrum Pharmaceuticals Inc. [SPPI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPPI shares is $5.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPPI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Spectrum Pharmaceuticals Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on September 17, 2020. The new note on the price target was released on December 26, 2019, representing the official price target for Spectrum Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $17 to $4, while Cantor Fitzgerald kept a Neutral rating on SPPI stock.
The Average True Range (ATR) for Spectrum Pharmaceuticals Inc. is set at 0.11 The Price to Book ratio for the last quarter was 6.82, with the Price to Cash per share for the same quarter was set at 0.37.
SPPI Stock Performance Analysis:
Spectrum Pharmaceuticals Inc. [SPPI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.82. With this latest performance, SPPI shares gained by 15.62% in over the last four-week period, additionally plugging by 63.59% over the last 6 months – not to mention a drop of -41.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPPI stock in for the last two-week period is set at 58.48, with the RSI for the last a single of trading hit 59.51, and the three-weeks RSI is set at 58.35 for Spectrum Pharmaceuticals Inc. [SPPI]. The present Moving Average for the last 50 days of trading for this stock 1.0363, while it was recorded at 1.2410 for the last single week of trading, and 1.0161 for the last 200 days.
Insight into Spectrum Pharmaceuticals Inc. Fundamentals:
Return on Equity for this stock declined to -174.30, with Return on Assets sitting at -102.77.
Spectrum Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.
Spectrum Pharmaceuticals Inc. [SPPI] Insider Position Details
There are presently around $76 million, or 31.80% of SPPI stock, in the hands of institutional investors. The top three institutional holders of SPPI stocks are: ARMISTICE CAPITAL, LLC with ownership of 17,100,000, which is approximately 0% of the company’s market cap and around 1.90% of the total institutional ownership; VANGUARD GROUP INC, holding 8,828,676 shares of the stock with an approximate value of $11.43 million in SPPI stocks shares; and D. E. SHAW & CO., INC., currently with $10.43 million in SPPI stock with ownership of nearly 2.627% of the company’s market capitalization.
Positions in Spectrum Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 39 institutional holders increased their position in Spectrum Pharmaceuticals Inc. [NASDAQ:SPPI] by around 5,922,192 shares. Additionally, 60 investors decreased positions by around 19,751,021 shares, while 23 investors held positions by with 32,929,159 shares. The mentioned changes placed institutional holdings at 58,602,372 shares, according to the latest SEC report filing. SPPI stock had 19 new institutional investments in for a total of 1,085,081 shares, while 33 institutional investors sold positions of 3,569,495 shares during the same period.